mp3 dönüştür

We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Ketogenic diet with chemo shows survival trend in pancreatic cancer

People with advanced pancreatic cancer who followed a ketogenic diet program administered by Virta Health while receiving chemotherapy tended to live longer than those treated with chemotherapy only, according to results from a small clinical trial. “Our randomized...

Inovio, Akeso partner on Phase 2 trial of new immunotherapy for glioblastoma

Inovio Pharmaceuticals and Akeso have entered into a clinical trial collaboration and supply agreement to evaluate a novel immunotherapy combining INO-5412 plus cadonilimab as a potential treatment for glioblastoma, an aggressive form of glioma. The Phase 2 INSIGhT...

Immune duo safely targets hard-to-treat gynecological cancers

A combination of two immune-modulating treatments, Lymphir (denileukin diftitox) and Keytruda (pembrolizumab), was well tolerated in an exploratory clinical trial of people with hard-to-treat gynecological cancers. The Phase 1/2 study (NCT05200559) is sponsored by...

Toward a cure for multiple myeloma within a decade

Source: Myeloma : nature.com subject feeds Post Content Read More

FDA approves Tecvayli, Darzalex Faspro in combo for hard-to-treat myeloma

The U.S. Food and Drug Administration (FDA) has approved the combination of Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) for treating certain people with multiple myeloma. The approval specifically covers myeloma patients whose...
Latest Data

Latest Publications

The [(18)F]FDG PET/CT for prognostic stratification in multiple myeloma: A systematic review and meta-analysis

Eur J Nucl Med Mol Imaging. 2026 Mar 7. doi: 10.1007/s00259-026-07830-5. Online ahead of print. NO...

Cluster of differentiation 38 monoclonal antibody therapy in the treatment of multiple myeloma: a systematic review and meta-analysis

Front Pharmacol. 2026 Feb 12;16:1687718. doi: 10.3389/fphar.2025.1687718. eCollection 2025....

Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysis

Leukemia. 2026 Feb 17. doi: 10.1038/s41375-026-02880-y. Online ahead of print. NO ABSTRACT...

The impact of cardiac amyloidosis on patients with multiple myeloma: a systematic review and meta-analysis

Cardiooncology. 2026 Feb 10. doi: 10.1186/s40959-025-00435-1. Online ahead of print. NO ABSTRACT...

Email

info@myeloma360.com

bahisliongalabet1xbet